Lurbinectedin Approval and Key Trial Data
Lurbinectedin (brand name Zepzelca) gained accelerated FDA approval in June 2020 for adults with metastatic small cell lung cancer (SCLC) that progressed after platinum-based chemotherapy.[1] The pivotal trial was a multicenter, open-label phase 2 basket trial (PM14-504) with 105 patients, primarily those with relapsed SCLC (80%). The primary endpoint was overall response rate (ORR) by independent review, hitting 35% (95% CI: 26-45).[1][2]
Response Rates by Subgroup
In the SCLC cohort:
- Sensitive relapse (first-line response ≥90 days): ORR 51% (20/39 patients).
- Resistant relapse (<90 days): ORR 22% (13/60 patients).[2]
Median duration of response was 5.3 months overall, with 46% of responders maintaining response at 6 months.[1]
Median progression-free survival (PFS) was 3.5 months; overall survival (OS) was 9.3 months.[2] Updated analyses from the phase 3 confirmatory trial (ORR 41% with immunotherapy combo) supported full approval in 2024.[3]
Comparison to Standard Treatments
Lurbinectedin outperformed topotecan (historical ORR 15-24% in similar SCLC patients) and showed non-inferior OS in head-to-head trials.[2][4] It's not first-line but second-line standard now.
Ongoing Trials and Limitations
Phase 3 trials like LAGOON (NCT05143218, first-line SCLC with atezolizumab) report interim ORR around 60-70% in combos, but monotherapy data remains from smaller relapsed cohorts.[5] Success varies by prior immunotherapy exposure—lower ORR (25%) post-anti-PD-1.[2] No large-scale data for non-SCLC uses yet.
[1]: FDA Approval Summary: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer
[2]: Trigo et al., Lancet Oncology (2020): https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30268-0/fulltext
[3]: ASCO 2024 Abstract: https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.8503
[4]: Paz-Ares et al., Lancet Oncology (2021): https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00065-2/fulltext
[5]: ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT05143218